No medication changes are needed for an asymptomatic blood glucose of 68 mg/dL on Wegovy 1.7 mg weekly.
GLP-1 receptor agonists like semaglutide (Wegovy) have minimal risk for hypoglycemia when used as monotherapy because they stimulate insulin secretion in a glucose-dependent manner 1. This patient's glucose of 68 mg/dL, while technically at the hypoglycemia alert threshold, does not require intervention in the absence of symptoms.
Why This Patient Is Safe
The key distinction here is that GLP-1 receptor agonists only trigger insulin release when glucose levels are elevated. As glucose falls, the insulinotropic effect diminishes, creating an inherent safety mechanism against severe hypoglycemia 1. The FDA label for Wegovy confirms this by stating that blood glucose monitoring is primarily indicated "in patients with type 2 diabetes mellitus" 2, not in patients using it for weight management alone.
When to Intervene
You should only consider medication adjustments if:
- Symptomatic hypoglycemia develops (tremors, sweating, confusion, palpitations) 3
- Recurrent glucose readings <70 mg/dL occur, even if asymptomatic 3
- The patient is on concurrent medications that increase hypoglycemia risk: insulin, sulfonylureas, or meglitinides 1
Recent research confirms that patients with normal BMI and HbA1c <7% are at higher risk for hypoglycemia on semaglutide 4. However, this patient is presumably overweight/obese (given Wegovy indication) and likely does not have diabetes, placing them in a lower-risk category.
Clinical Monitoring Plan
Rather than changing the medication:
- Educate the patient to recognize hypoglycemia symptoms and treat with 15g fast-acting carbohydrates if glucose <70 mg/dL with symptoms 3
- Recheck glucose if symptoms develop, particularly during the first 3 months of therapy when hypoglycemia risk is highest 4
- Ensure adequate caloric intake - the reduced-calorie diet required with Wegovy should not be so restrictive as to cause recurrent low glucose 2
- Continue current Wegovy dose of 1.7 mg weekly without adjustment 2
Important Caveats
If this patient were on insulin or sulfonylureas concurrently, you would need to reduce those medications immediately, as GLP-1 receptor agonists "may increase the hypoglycemic potential of insulin and sulfonylureas when combined" 1. The sick day medication guidance consensus recommends temporarily holding these agents during illness or volume depletion 5, but this does not apply to an asymptomatic outpatient scenario.
The absence of symptoms is the critical factor here - a single glucose reading of 68 mg/dL without clinical manifestations does not constitute true hypoglycemia requiring treatment or medication adjustment in a patient on GLP-1 monotherapy.